Vor Biopharma (NASDAQ:VOR) Issues Earnings Results, Misses Estimates By $0.11 EPS

Vor Biopharma (NASDAQ:VOR) issued its quarterly earnings data on Tuesday. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.11), Zacks reports.

Vor Biopharma Trading Down 1.2%

VOR traded down $0.27 on Tuesday, hitting $23.10. 88,711 shares of the stock traded hands, compared to its average volume of 1,068,459. The business has a fifty day moving average price of $17.80 and a two-hundred day moving average price of $15.84. Vor Biopharma has a 52 week low of $6.50 and a 52 week high of $50.20.

Analysts Set New Price Targets

A number of brokerages recently issued reports on VOR. Wedbush upped their price objective on shares of Vor Biopharma from $15.00 to $18.00 and gave the stock a “neutral” rating in a report on Thursday, May 14th. Jefferies Financial Group upgraded Vor Biopharma to a “strong-buy” rating in a research note on Thursday, April 30th. Wall Street Zen downgraded Vor Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Weiss Ratings raised Vor Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, June 30th. Finally, HC Wainwright reissued a “buy” rating and issued a $31.00 price target on shares of Vor Biopharma in a research report on Monday, May 18th. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $42.25.

Institutional Trading of Vor Biopharma

A number of institutional investors and hedge funds have recently modified their holdings of the company. RA Capital Management L.P. lifted its position in Vor Biopharma by 172.7% in the fourth quarter. RA Capital Management L.P. now owns 5,404,998 shares of the company’s stock worth $70,697,000 after purchasing an additional 3,422,697 shares during the period. Paradigm Biocapital Advisors LP acquired a new position in shares of Vor Biopharma in the 4th quarter valued at $22,890,000. Caligan Partners LP bought a new position in shares of Vor Biopharma during the 4th quarter worth about $12,100,000. Sphera Funds Management LTD. bought a new position in shares of Vor Biopharma during the 4th quarter worth about $5,368,000. Finally, Laurion Capital Management LP acquired a new stake in shares of Vor Biopharma during the 4th quarter valued at about $4,150,000. 97.29% of the stock is currently owned by institutional investors.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).